Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters - PubMed (original) (raw)

Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters

Kathryn M Taylor et al. Biochem J. 2003.

Abstract

The LIV-1 gene has been previously associated with oestrogen-positive breast cancer and its metastatic spread to the regional lymph nodes. We have investigated the protein product of this gene as a marker for disease progression of breast cancer. The protein sequence contains a potential metalloprotease motif (HEX P H E XGD), which fits the consensus sequence for the catalytic zinc-binding site motif of the zincin metalloproteases. This motif has identified a new subfamily of ZIP (Zrt-, Irt-like proteins) zinc transporters, which we have termed LZT (LIV-1 subfamily of ZIP zinc transporters). Expression of recombinant LIV-1 in Chinese-hamster ovary cells confirmed the prediction that LZT proteins can act as zinc-influx transporters. Zinc is essential for growth and zinc transporters have an important role in maintaining intracellular zinc homoeostasis, aberrations of which could lead to diseases such as cancer. This is the first report of the expression of a recombinant human LZT protein in mammalian cells. Recombinant LIV-1 locates to the plasma membrane, concentrated in lamellipodiae, similar to membrane-type metalloproteases. Examination of LIV-1 tissue expression located it mainly to hormonally controlled tissues with widespread expression in the brain. Interestingly, the LIV-1 sequence contains a strong PEST site and other potential degradation motifs, which, combined with our evidence that recombinant LIV-1 associates with ubiquitin, may explain the low-level expression of LIV-1. Combining the crucial role that zinc plays in cell growth and the proven role of metalloproteases in metastasis presents an exciting indication of how LIV-1 plays a role in breast cancer progression.

PubMed Disclaimer

Cited by

ZIP4: a promising early diagnostic and therapeutic targets for pancreatic cancer.
Tang Y, Guo S, Yu N, Li H. Tang Y, et al. Am J Cancer Res. 2024 Sep 25;14(9):4652-4664. doi: 10.62347/AVYM3477. eCollection 2024. Am J Cancer Res. 2024. PMID: 39417191 Free PMC article. Review.
Antibody-Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?
De Santis P, Sanna V, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, Oliva GR, Fancellu A, Fedele P. De Santis P, et al. J Clin Med. 2023 Nov 26;12(23):7325. doi: 10.3390/jcm12237325. J Clin Med. 2023. PMID: 38068376 Free PMC article. Review.
Zinc Ions Modulate YY1 Activity: Relevance in Carcinogenesis.
Figiel M, Górka AK, Górecki A. Figiel M, et al. Cancers (Basel). 2023 Aug 30;15(17):4338. doi: 10.3390/cancers15174338. Cancers (Basel). 2023. PMID: 37686614 Free PMC article. Review.
Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions.
Morrison L, Okines A. Morrison L, et al. Cancers (Basel). 2023 Jul 26;15(15):3801. doi: 10.3390/cancers15153801. Cancers (Basel). 2023. PMID: 37568617 Free PMC article. Review.
The role of Zn2+ in shaping intracellular Ca2+ dynamics in the heart.
Dorward AM, Stewart AJ, Pitt SJ. Dorward AM, et al. J Gen Physiol. 2023 Jul 3;155(7):e202213206. doi: 10.1085/jgp.202213206. Epub 2023 Jun 16. J Gen Physiol. 2023. PMID: 37326614 Free PMC article. Review.

References

1. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14765-70 - PubMed
1. Immunology. 1997 May;91(1):20-7 - PubMed
1. J Biol Chem. 2000 Feb 25;275(8):5560-4 - PubMed
1. Brain Res. 1999 Nov 27;848(1-2):45-62 - PubMed
1. IUBMB Life. 2000 Apr;49(4):249-53 - PubMed

Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters - PubMed (original) (raw)